1. Home
  2. INGN vs MDWD Comparison

INGN vs MDWD Comparison

Compare INGN & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.27

Market Cap

168.6M

Sector

Health Care

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.31

Market Cap

193.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
MDWD
Founded
2001
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Specialties
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.6M
193.3M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
INGN
MDWD
Price
$6.27
$16.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$11.00
$36.00
AVG Volume (30 Days)
224.0K
68.4K
Earning Date
05-06-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
N/A
EPS
N/A
N/A
Revenue
$348,668,000.00
N/A
Revenue This Year
$7.92
$48.88
Revenue Next Year
$7.86
$35.08
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$5.34
$14.14
52 Week High
$9.13
$22.51

Technical Indicators

Market Signals
Indicator
INGN
MDWD
Relative Strength Index (RSI) 51.57 46.12
Support Level $6.26 N/A
Resistance Level $6.83 $18.71
Average True Range (ATR) 0.25 0.64
MACD -0.01 -0.07
Stochastic Oscillator 51.55 54.55

Price Performance

Historical Comparison
INGN
MDWD

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: